A potential peptide vaccine against two different strains of influenza virus isolated at intervals of about 10 years.

Naruse, Hirohito; Ogasawara, Kunio; Kaneda, Rika; Hatakeyama, Susumi; Itoh, Toshihiro; Kida, Hiroshi; Miyazaki, Tamotsu; Good, Robert A.; Onoé, Kazunori

doi:10.1073/pnas.91.20.9588

Cited by 23 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, combined with the above-mentioned data of the protection from a challenge with the A/Texas strain, the re sults demonstrate that the vaccine combining all three influ enza epitopes was effective against at least four different influenza strains. This conclusion is corroborated by a re cent report in which another conserved HA epitope from the H3 subtype led to protective immunity against two H3 strains [48],…”

Section: Cross-protection Against Various A/lnjhienza Strainssupporting

confidence: 73%

Synthetic Recombinant Vaccines against Viral Agents

Arnon¹,

Levi²

1995

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Synthetic recombinant vaccines are expression vectors incorporating defined epitope(s) of microbial agents. They are prepared by inserting synthetic oligonucleotide(s) coding for previously identified relevant epitopes into the genome of a desired vector, using recombinant DNA technology. The results discussed indicate that immunization with such vaccines carrying viral epitopes may lead to protective immunity against viral agents. Oligonucleotides coding for three influenza epitopes stimulating B cells, T helper cells and cytotoxic lymphocytes were individually inserted into the flagellin gene of a Salmonella vaccine strain. Immunization of mice with the resultant recombinant bacteria or their isolated flagella induced a specific mucosal anti-influenza protective response. The most efficient vaccine consisted of all three recombinant flagella, administered intranasally. The protection elicited was cross-strain specific, long-lasting and efficient against a lethal viral challenge.

show abstract

Section: Cross-protection Against Various A/lnjhienza Strainssupporting

confidence: 73%

Synthetic Recombinant Vaccines against Viral Agents

Arnon¹,

Levi²

1995

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…Alternatively, influenza vaccines could be designed to include only those regions of HA that correspond to epitopes with high neutralization efficiencies. Peptide-based influenza vaccines were proposed (27), but there has been little focus on peptides that correspond to epitopes with high neutralization efficiencies. Furthermore, antiinfluenza viral drugs could be designed to include HA proteins carrying modifications to high-neutralization efficiency epitopes; these modified HA proteins would compete with virus for binding to low-neutralization efficiency antibodies in a manner akin to the role played by neuraminidase inhibitors (28).…”

Section: Resultsmentioning

confidence: 99%

Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines

Ndifon¹,

Wingreen

Levin³

2009

Proc. Natl. Acad. Sci. U.S.A.

103

View full text Add to dashboard Cite

It is generally assumed that amino acid mutations in the surface protein, hemagglutinin (HA), of influenza viruses allow these viruses to circumvent neutralization by antibodies induced during infection. However, empirical data on circulating influenza viruses show that certain amino acid changes to HA actually increase the efficiency of neutralization of the mutated virus by antibodies raised against the parent virus. Here, we suggest that this surprising increase in neutralization efficiency after HA mutation could reflect steric interference between antibodies. Specifically, if there is a steric competition for binding to HA by antibodies with different neutralization efficiencies, then a mutation that reduces the binding of antibodies with low neutralization efficiencies could increase overall viral neutralization. We use a mathematical model of virus-antibody interaction to elucidate the conditions under which amino acid mutations to HA could lead to an increase in viral neutralization. Using insights gained from the model, together with genetic and structural data, we predict that amino acid mutations to epitopes C and E of the HA of influenza A/H3N2 viruses could lead on average to an increase in the neutralization of the mutated viruses. We present data supporting this prediction and discuss the implications for the design of more effective vaccines against influenza viruses and other pathogens.antigenic distance ͉ epidemic ͉ epitope vaccine ͉ evolution

show abstract

“…Determination of peptides that elicit a T-cell response in vivo is important for identifying autoimmune (Alegretta et al, 1990;Protti et al, 1993) and CTL (Kane et al, 1989;Kast et al, 1994;Nijman et al, 1993) epitopes and for peptide vaccine design (Herrington et al, 1987;Naruse et al, 1994;. While suf®cient conditions for a peptide to be a T-cell epitope are not well known, one well established (Buus et al, 1987) necessary condition is that they bind MHC molecules.…”

Section: Introductionmentioning

confidence: 98%